Trial Outcomes & Findings for Moxibustion in a Randomized Trial for Version of Breech Position From Week 32 (NCT NCT02251886)
NCT ID: NCT02251886
Last Updated: 2017-03-03
Results Overview
Number of Participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
200 participants
Primary outcome timeframe
4 weeks
Results posted on
2017-03-03
Participant Flow
Participant milestones
| Measure |
Moxibustion in Primiparae
Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
Moxibustion in primiparae: Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
|
Moxibustion in Multiparae
Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
Moxibustion in multiparae: Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
|
Control Primiparae
No intervention. Routine control schedule for primiparae with midwife
|
Control Multiparae
No intervention. Routine control schedule for multiparae with midwife
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
48
|
54
|
44
|
54
|
|
Overall Study
COMPLETED
|
48
|
54
|
44
|
54
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Moxibustion in a Randomized Trial for Version of Breech Position From Week 32
Baseline characteristics by cohort
| Measure |
Moxibustion in Primiparae
n=48 Participants
Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
Moxibustion in primiparae: Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
|
Moxibustion in Multiparae
n=54 Participants
Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
Moxibustion in multiparae: Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
|
Control Primiparae
n=44 Participants
No intervention. Routine control schedule for primiparae with midwife
|
Control Multiparae
n=54 Participants
No intervention. Routine control schedule for multiparae with midwife
|
Total
n=200 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
48 Participants
n=5 Participants
|
54 Participants
n=7 Participants
|
44 Participants
n=5 Participants
|
54 Participants
n=4 Participants
|
200 Participants
n=21 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Age, Continuous
|
28 years
STANDARD_DEVIATION 4 • n=5 Participants
|
31 years
STANDARD_DEVIATION 3 • n=7 Participants
|
29 years
STANDARD_DEVIATION 4 • n=5 Participants
|
31 years
STANDARD_DEVIATION 3 • n=4 Participants
|
30 years
STANDARD_DEVIATION 4 • n=21 Participants
|
|
Gender
Female
|
48 Participants
n=5 Participants
|
54 Participants
n=7 Participants
|
44 Participants
n=5 Participants
|
54 Participants
n=4 Participants
|
200 Participants
n=21 Participants
|
|
Gender
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Region of Enrollment
Denmark
|
48 participants
n=5 Participants
|
54 participants
n=7 Participants
|
44 participants
n=5 Participants
|
54 participants
n=4 Participants
|
200 participants
n=21 Participants
|
|
Weight
|
76 kg
STANDARD_DEVIATION 14 • n=5 Participants
|
78 kg
STANDARD_DEVIATION 14 • n=7 Participants
|
75 kg
STANDARD_DEVIATION 12 • n=5 Participants
|
74 kg
STANDARD_DEVIATION 15 • n=4 Participants
|
76 kg
STANDARD_DEVIATION 14 • n=21 Participants
|
|
Gestational age
|
229 days
STANDARD_DEVIATION 6 • n=5 Participants
|
230 days
STANDARD_DEVIATION 6 • n=7 Participants
|
230 days
STANDARD_DEVIATION 7 • n=5 Participants
|
231 days
STANDARD_DEVIATION 7 • n=4 Participants
|
230 days
STANDARD_DEVIATION 6 • n=21 Participants
|
PRIMARY outcome
Timeframe: 4 weeksNumber of Participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
Outcome measures
| Measure |
Moxibustion in Primiparae
n=48 Participants
Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
Moxibustion in primiparae: Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
|
Moxibustion in Multiparae
n=54 Participants
Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
Moxibustion in multiparae: Moxibustion at acupuncture point Bl 67 daily for 15-20 minutes for 3-4 weeks in multiparae
|
Control Primiparae
n=44 Participants
No intervention. Routine control schedule for primiparae with midwife
|
Control Multiparae
n=54 Participants
No intervention. Routine control schedule for multiparae with midwife
|
|---|---|---|---|---|
|
Number of Participants With Version of Fetal Breech Position to Cephalic Position up to 4 Weeks After Treatment
|
34 participants
|
25 participants
|
34 participants
|
25 participants
|
Adverse Events
Moxibustion in Primiparae
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Moxibustion in Multiparae
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control Primiparae
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control Multiparae
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place